The bacterium Mycobacterium tuberculosis (Mtb) causes tuberculosis (TB) and is 2 responsible for more human mortality than any other single pathogen 1 . Although ~1.7 3 billion people are infected with Mtb 2 , most infections are asymptomatic. Progression to 4 active disease occurs in ~10% of infected individuals and is predicted by an elevated type 5
Introduction 23
Mycobacterium tuberculosis (Mtb) infects approximately one quarter of all humans 24 worldwide 2 , with highly diverse outcomes ranging from asymptomatic lung granulomas 25 to lethal disseminated disease. Active TB disease is characterized by the uncontrolled 26 replication of bacteria and pathological inflammation in the lungs and other organs, and 27
arises in approximately 10% of infected HIV-negative individuals. There is no vaccine 28 that reliably protects against pulmonary TB, and although antibiotics can be curative, the 29 long (≥6-month) course of treatment and increasing prevalence of multi-drug resistant 30
Mtb infections has spurred a search for alternative therapeutic approaches 13, 14 . Since only 31 individuals with active TB readily transmit infection, and as humans are the only natural 32 reservoir of Mtb, a favored strategy to contain the TB epidemic is to identify and treat 33 latently infected individuals likely to progress to active disease 1, 3 . Identification of such 34 individuals is challenging, but recent studies have demonstrated that an enhanced type I 35 interferon (IFN) signature correlates with active TB 5, 6, 8 and can predict progression to 36 active TB up to 18 months prior to diagnosis 3, 4 . A partial loss-of-function polymorphism 37 in the type I IFN receptor (IFNAR1) is associated with resistance to TB in humans, 38
suggesting that elevated levels of type I IFNs not only predict but may even be causally 39 linked to TB progression 15 . In addition, numerous animal studies have demonstrated 40 causal roles for type I IFNs in susceptibility to Mtb 6, 7, 16, 17 and other bacterial 41 infections 11, 12 . 42
Given strong evidence that type I IFNs confer susceptibility to human TB, two 43 major remaining challenges are: (1) to determine the mechanisms by which type I IFNs 44 mediate susceptibility to active TB, and (2) to exploit this knowledge to develop 45 interventions that can reverse the susceptibility. Mechanistic studies and initial trials of 46 possible therapeutic interventions require a robust animal model. However, the most 47 commonly used animal model, the C57BL/6 (B6) mouse, does not robustly recapitulate 48 the interferon-driven TB susceptibility seen in humans. B6 Ifnar -/-mice show mild 49 resistance to Mtb in the spleen and variable but modest effects in the lungs [18] [19] [20] . To better 50 model IFN-driven susceptibility, some investigators treat Mtb-infected B6 mice with 51 poly-IC, a potent inducer of type I IFNs 21 . Such treatment dramatically increases 52 susceptibility to Mtb in an Ifnar-dependent manner 21, 22 , but because the IFN is induced 53 -3-artificially and not by Mtb itself, it is unclear if poly-IC mimics the course of IFN-driven 54 disease in humans. 55
As an alternative approach, we sought to exploit the natural diversity of available 56 inbred mouse strains. The 129 mouse strain shows clear IFN-driven susceptibility to 57
Mtb
23 , but there are limited tools on this genetic background. We therefore turned to a 58 previously described congenic mouse strain, B6.Sst1
S , that carries the 10.7Mb 'super 59 susceptibility to tuberculosis 1' region of mouse chromosome 1 from C3H on an 60 otherwise B6 genetic background 9, 10 34 , and/or decreased IL-1 levels 35, 36 . We 101 did not observe significant differences in IL-10 or IFNγ levels in the lung during in vivo 102
Mtb infection (Fig. S3a,b) . In addition, crossing B6.Sst1 S mice to B6.Ch25h -/-mice did 103 not alter day 25 lung bacterial burdens (Fig. S3c) . Moreover, despite clear evidence that 104 type I IFN and IL-1 counter-regulate each other 37 , the Sst1 S locus did not appear to act to 105 decrease the levels of IL-1 in vivo; in fact, we unexpectedly observed higher levels of 106 both IL-1α and IL-1β in the lungs of B6.Sst1 S mice at 25 days post-infection as compared 107 to B6 mice (Fig. 2a,b) . Other inflammatory cytokines, including TNF and CXCL1 were 108 similarly elevated in the B6.Sst1 S mice (Fig. S3d,e) as was the frequency of 109
CD11b
+ Ly6G + cells (neutrophils) in the lungs (Fig. S3f) . The elevated inflammation in 110 B6.Sst1 S mice was a consequence of elevated type I IFNs, as inflammatory cytokines and 111 neutrophils were reduced in B6.Sst1
S Ifnar -/-mice, but the underlying mechanism was not 112
apparent. 113
We reasoned that the high levels of IL-1α/β in B6.Sst1 S mice may be a 114 consequence of the higher bacterial burdens in these mice, or alternatively, may be 115 causing increased bacterial replication via induction of a pro-bacterial inflammatory 116 milieu, as previously proposed 38, 39 . To distinguish these possibilities, we inhibited IL-1 (Fig. 4a) . Notably, a partial reduction in IL-1Ra levels due to 153 heterozygous deficiency of Il1rn was sufficient to almost entirely reverse the enhanced 154 IFN-driven susceptibility of Sst1 S mice (Fig. 4b) (Fig. 4b, Fig.S5a ). 160
The dramatic protective effects of even partial reductions in IL-1Ra suggested 161 that IL-1Ra might be a suitable target for host-directed therapy during Mtb infection. To 162 test this idea, we treated infected B6.Sst1
S mice with an anti-IL-1Ra antibody 57 to block 163 IL-1Ra and restore IL-1 signaling (Fig. 4d) . B6.Sst1 S mice that received the antibody for 164 two weeks had significantly lower bacterial burdens in their lungs as compared to those 165 receiving a control injection of PBS. In addition, mice treated with anti-IL-1Ra antibody 166 retained significantly more body weight than their control counterparts (Fig. 4e) , and 167 exhibited reduced lung lesions (Fig. 4f) Analyzed with two-ended Mann-Whitney test (a, b, d, e) . Asterisk, p ≤ 0.05; two asterisks, p ≤ 0.01; three asterisks, p ≤ 0.001. Combined results of two independent infections. All animals except B6 were bred in-house (a-e); all animals were bred in-house (f). Error bars are SEM. Analyzed with two-ended Mann-Whitney test (a-f). Asterisk, p ≤ 0.05; two asterisks, p ≤ 0.01; three asterisks, p ≤ 0.001. 
